Analysis Of Income And Expense [Abstract]

Egetis Therapeutics - Filing #678413

Concept 2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
Analysis of income and expense [abstract]
Revenue [abstract]
Revenue
576,000,000 SEK
226,000,000 SEK
Material income and expense [abstract]
Miscellaneous other operating expense
46,000,000 SEK
11,000,000 SEK
Revenue and other operating income
576,000,000 SEK
226,000,000 SEK
Gains (losses) on change in fair value of derivatives [abstract]
Gains (losses) on change in fair value of derivatives
27,000,000 SEK
- SEK
Expenses by nature [abstract]
Classes of employee benefits expense [abstract]
Employee benefits expense
840,000,000 SEK
520,000,000 SEK
Depreciation, amortisation and impairment loss (reversal of impairment loss) recognised in profit or loss [abstract]
Depreciation, amortisation and impairment loss (reversal of impairment loss) recognised in profit or loss
36,000,000 SEK
27,000,000 SEK
Other expenses, by nature
858,000,000 SEK
223,000,000 SEK
Comprehensive income, continuing and discontinued operations [abstract]
Comprehensive income
- SEK
- SEK
3,270,000,000 SEK
3,270,000,000 SEK
- SEK
- SEK
- SEK
1,938,000,000 SEK
1,938,000,000 SEK
- SEK

Talk to a Data Expert

Have a question? We'll get back to you promptly.